Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Chavant Capital Acquisition Corp. | Director | Class A Common Stock | 541K | $5.41M | $10.00 | Dec 21, 2023 | Indirect |
Bionik Laboratories Corp. | Director | Common Stock | 1.11M | $666K | $0.60 | Jun 13, 2023 | Shares held through Star SCI |
Chavant Capital Acquisition Corp. | Director | Class A Common Stock | 27.8K | $278K | $10.00 | Dec 21, 2023 | Direct |
Bionik Laboratories Corp. | Director | Common Stock | 95.1K | $57.1K | $0.60 | Jun 13, 2023 | Direct |
Bionik Laboratories Corp. | Director | Common Stock | 10.7K | $6.42K | $0.60 | Jun 13, 2023 | Shares held through 4A Consulting and Engineering |
Chavant Capital Acquisition Corp. | Director | Make-Whole Shares (right to acquire) | 145K | Dec 21, 2023 | Indirect | ||
Bionik Laboratories Corp. | Director | Convertible Promissory Note | 1 | Jun 13, 2023 | Through Star SCI |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
MOBX | Chavant Capital Acquisition Corp. | Dec 21, 2023 | 3 | $1.45M | 4 | Dec 26, 2023 | Director |
BNKL | Bionik Laboratories Corp. | Jun 13, 2023 | 2 | $332K | 4 | Jun 21, 2023 | Director |
BNKL | Bionik Laboratories Corp. | Jun 9, 2023 | 1 | $390K | 4 | Jun 21, 2023 | Director |
CLAY | Chavant Capital Acquisition Corp. | Feb 24, 2022 | 1 | $0 | 4 | Feb 28, 2022 | Director |
CLAY | Chavant Capital Acquisition Corp. | Jul 19, 2021 | 0 | $0 | 3 | Jul 20, 2021 | Director |
BNKL | Bionik Laboratories Corp. | Jul 15, 2021 | 4 | $210K | 4 | Jun 21, 2022 | Director |